Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGRX-326 Extension Study in NSCLC
CTR20242826Phase 3Active
- Sponsor
- Shenzhen Tagrisso Biopharmaceutical
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deulorlatinib in non-small cell lung cancer (NSCLC), sponsored by Shenzhen Tagrisso Biopharmaceutical. Started Aug 2024; status: active.
02
Drugs
deulorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20242826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242826.